GHRP-6: Evidence, Mechanism, Dosing & Legal Status

GHRP-6 ("growth hormone releasing peptide-6," developmental code SKF-110679) is a synthetic hexapeptide growth hormone secretagogue marketed in fitness circles for recovery, muscle and appetite. Unlike most peptides in this category it has genuine human data — but that data is almost entirely acute neuroendocrine challenge studies and small pediatric trials, not therapeutic outcome RCTs.3 This monograph separates the proven acute effects from the marketed claims.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. GHRP-6 is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is GHRP-6 and how does it work?

GHRP-6 is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, derived by Cyril Bowers and colleagues in the 1980s from structure-activity work on met-enkephalin analogues. It was the first synthetic compound shown to specifically and dose-dependently release growth hormone through a mechanism distinct from GHRH.3 Historically, the hunt for the GHRP-6 receptor led to identification of the growth hormone secretagogue receptor (GHS-R1a) in 1996 and, in 1999, to ghrelin, its endogenous ligand — making GHRP-6 a foundational pharmacological tool.3

The mechanism flows from a single target. GHRP-6 is an agonist at GHS-R1a, the ghrelin receptor, and two consequences follow. First, GH release: acting principally at the hypothalamus, GHRP-6 evokes a GH pulse and acts synergistically with GHRH, so co-administration yields GH release exceeding the sum of each alone. In patients with hypothalamo-pituitary disconnection, GHRP-6-induced GH secretion is blocked and its synergy with GHRH disappears, indicating it works upstream of and together with endogenous GHRH.3 Second, appetite stimulation: because GHS-R1a is the same receptor endogenous ghrelin uses to signal hunger, GHRP-6 is a ghrelin mimetic that activates orexigenic NPY/AgRP neurons in the hypothalamic arcuate nucleus, driving food intake.3 GHRP-6 is also non-selective: it additionally stimulates ACTH/cortisol and prolactin, the very property used to define ipamorelin's superior selectivity by contrast.2 Pharmacokinetically it has a short plasma half-life of about 20 minutes and very low oral bioavailability near 0.3%, which is precisely why later non-peptide secretagogues such as ibutamoren were developed for oral use.3

What is the evidence by indication?

GHRP-6 has more real human data than most peptides in its class, but it is overwhelmingly acute-challenge and pediatric data, not therapeutic outcome trials. No GHRP-6 study demonstrates a hard clinical endpoint such as reduced fractures, improved survival or durable body-composition change. The grading below reflects that maturity gap.

The growth hormone effect is the best documented. In a controlled pediatric study of children with normal short stature, oral GHRP-6 at 300 micrograms per kilogram produced a GH peak of 18.8 plus or minus 3.0 micrograms per litre at 60 minutes — comparable to maximally effective IV GHRH-29 at 1 microgram per kilogram (peak 20.8 plus or minus 4.5 micrograms per litre at 45 minutes) — and oral arginine further potentiated the response.1 Reviews note the near-maximal IV bolus is about 1 microgram per kilogram.3 What this proves is that GHRP-6 is a robust GH secretagogue in humans; what it does not prove is that the GH rise yields any durable clinical benefit. The appetite effect is, via GHS-R1a/ghrelin mimicry, a direct and predictable pharmacodynamic action rather than a downstream GH consequence — the basis for any putative use in cachexia or underweight states, though the ghrelin-axis appetite drugs that actually advanced clinically, such as anamorelin, are separate molecules.3

What doses appear in the literature?

Reported strictly as information, not a protocol. There is no standardized FDA-validated dosing because GHRP-6 is unapproved. In challenge studies about 1 microgram per kilogram intravenously is the commonly cited near-saturation bolus for maximal GH release, with peak GH within roughly 15 to 30 minutes.3 Subcutaneous use is reported in practice and research around 100 micrograms per injection (about 1 to 2 micrograms per kilogram) on an empty stomach, giving a lower but more prolonged GH peak than IV.1 The oral pediatric study used 300 micrograms per kilogram to overcome the roughly 0.3% oral bioavailability.1 A timing rationale recurs in the literature: elevated glucose and insulin after a meal blunt the GH response, hence the empty-stomach framing.3 The compound is supplied as a lyophilized powder requiring reconstitution for injection, and its short half-life is why frequent dosing appears in informal protocols.3

How safe is GHRP-6?

The most consistent and predictable effect is intense appetite, with onset around 15 to 30 minutes.3 The most clinically important documented concern for growth hormone secretagogues as a class is glucose dysregulation: IGF-1 elevation reduces insulin sensitivity, and class trials show rising fasting glucose and HbA1c, with one report of glucose roughly 25 to 27% above baseline, so the authors explicitly recommend monitoring glucose and HbA1c.3 Because GHRP-6 is non-selective it also raises cortisol/ACTH and prolactin in a dose-dependent way, more pronounced above the GH-saturation threshold — a defining contrast with ipamorelin.2 Fluid retention with mild peripheral edema, transient flushing, dizziness and injection-site reactions are reported.3 A class signal worth flagging: a hip-fracture secretagogue trial was halted early for a possible congestive-heart-failure increase (6.5% versus 1.7% placebo), though baseline blood-pressure differences may have confounded it — illustrating the thin long-term safety base.3 The dominant theoretical concern is that sustained GH/IGF-1 elevation could promote pre-existing malignancy; the class review states plainly that no malignancy or mortality safety data exist for these agents.3 Active or prior malignancy, pregnancy and lactation, and uncontrolled diabetes or significant insulin resistance are precautionary contraindications.

What is the FDA and WADA status in 2026?

GHRP-6 has no FDA approval for any indication and is not a recognized therapeutic or dietary-supplement ingredient.3 In September 2023 the FDA moved over a dozen peptides — including GHRP-6 — into 503A Category 2 (bulk drug substances that may present significant safety risks), effectively prohibiting their use in compounding under Sections 503A/503B.4 In 2026 the FDA removed a set of peptides from the explicit Category 2 list, but except for GHK-Cu none were recategorized to Category 1, leaving them in a gray zone: no longer flagged as a significant safety risk, yet not affirmatively authorized for compounding.5 The July 23-24, 2026 Pharmacy Compounding Advisory Committee slate covers seven other peptides, and a later session covers a different set; GHRP-6 appears on neither, and commentary expects GHRP-2 and GHRP-6 to remain restricted.5 Even reclassification would govern compounding legality only — it would confer no FDA approval, validated indication or standardized dosing.

For athletes the picture is unambiguous. GHRP-6 is explicitly named on the WADA 2026 Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), subsection S2.2.4 (Growth Hormone-Releasing Peptides), prohibited both in and out of competition and classified as non-specified, which carries the strictest sanctions.6 The 2026 list expanded the GHRP/GHS examples and reinforced the catch-all covering substances of similar chemical structure or biological effect to close analogue loopholes.7 The short plasma half-life means the direct detection window is brief, but biomarker signatures such as IGF-1 and GH pulsatility persist, and prohibition is class-based regardless.6

Bottom line. GHRP-6 is a historically important, mechanistically well-understood ghrelin-receptor agonist that genuinely triggers a GH pulse and a strong appetite surge in humans (grade B), and it is the molecule that led to discovery of the GHS-R and ghrelin. What is proven is the acute effect; what is hyped is durable recovery, muscle, fat-loss and anti-aging benefit, for which there are no GHRP-6 RCTs and no hard-endpoint data (grade D). Its non-selectivity — cortisol and prolactin elevation, reduced insulin sensitivity, fluid retention — is the chief liability and the explicit reason the selective ipamorelin was engineered. It is unapproved by the FDA and expected to stay restricted through 2026, banned by WADA at all times, and lacks the long-term malignancy and mortality safety data that any responsible human use would require. Regulatory facts here are current as of June 2026 and should be re-verified after the July 2026 PCAC session.